Skip to main content
For laboratory research use only. Not for human or veterinary use.
Free UPS Ground on 3+ vials · same business day by 2 PM ET
GLP-1 family

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Wilding JPH, Batterham RL, Calanna S, et al. · N Engl J Med · 2021
PMID: 33567185 · DOI: 10.1056/NEJMoa2032183
Summary

Phase 3 randomized, double-blind, placebo-controlled trial (STEP 1) of once-weekly semaglutide 2.4 mg vs placebo in 1961 adults with overweight/obesity without diabetes; 68 weeks. Primary endpoint: percent change in body weight.

Read the full citation on PubMed

Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.

Compounds referenced in this study
  • GLP-1 S
    Single-receptor incretin class agonist studied in incretin-pathway metabolic research.
    View product →
Guides covering this compound
More GLP-1 family citations
Browse the catalog